Term ends Jul 7, 2028 · High confidence
20-year base term ends Jul 7, 2028
Jul 7, 2008
Jul 7, 2028
Oct 17, 2017
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 7, 2008, when application 12/168,331, the earliest non-provisional in its chain, was filed (this one was filed Jun 2, 2016) | Jul 7, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,994,206, US 8,691,860, US 8,859,604, US 9,115,091, US 9,364,489) | resolves to Jul 7, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 7, 2028 | High confidence |
This family
| US 7,994,206 | In force Mar 2029 | Mar 2029 |
| US 8,609,865 | In force Jul 2028 | Jul 2028 |
| US 8,691,860 | In force Jul 2028 | Jul 2028 |
| US 8,859,604 | In force Jul 2028 | Jul 2028 |
| US 9,115,091 | In force Jul 2028 | Jul 2028 |
| US 9,364,489 | In force Jul 2028 | Jul 2028 |
| US 9,789,125 | this patent Jul 2028 | Jul 2028 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 8, 2016 Reel 39370, frame 455 | Anzalone, Luigi; Villani, Frank J.; Teleha, Christopher A.; Feibush, Penina; Fegely, Barry | Janssen Pharmaceutica, N.v. | Assignment of Assignor's Interest |
| Aug 8, 2016 Reel 39370, frame 501 | Janssen Pharmaceutica, N.v. | Furiex Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Aug 8, 2016 Reel 39627, frame 706 | Furiex Pharmaceuticals, Inc. | Furiex Pharmaceuticals, LLC. | Change of Name |
| Aug 8, 2016 Reel 39370, frame 559 | Furiex Pharmaceuticals, LLC. | Furiex Holdings Unlimited Company | Assignment of Assignor's Interest |
| Aug 8, 2016 Reel 39370, frame 599 | Furiex Holdings Unlimited Company | Forest Tosara Limited | Assignment of Assignor's Interest |
| Aug 8, 2016 Reel 39628, frame 452 | Forest Tosara Limited | Forest Tosara Unlimited Company | Change of Name |
| Aug 8, 2016 Reel 39370, frame 635 | Forest Tosara Unlimited Company | Allergan Holdings Unlimited Company | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 7,994,206, US 8,691,860, US 8,859,604, US 9,115,091, US 9,364,489, ends no earlier than this term, so it caps nothing.